Published in J Immunol on April 15, 1995
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma | NCT00683670
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res (2005) 2.71
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 1.67
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol (2000) 1.66
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med (2005) 1.55
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother (1997) 1.47
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res (2003) 1.46
Adoptive cell transfer therapy. Semin Oncol (2007) 1.44
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res (2007) 1.42
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest (2013) 1.36
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther (2003) 1.28
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol (1999) 1.26
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother (2003) 1.21
Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med (2001) 1.20
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med (1998) 1.15
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol (2005) 1.14
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother (2002) 1.14
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer (2002) 1.14
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun (2009) 1.09
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol (2002) 1.09
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer (1999) 1.07
Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol (1999) 1.06
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A (2002) 1.03
Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer (2002) 1.00
Structural engineering of pMHC reagents for T cell vaccines and diagnostics. Chem Biol (2007) 0.99
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother (2006) 0.96
Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol (2012) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest (1998) 0.89
Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res (2001) 0.88
Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides. J Biol Chem (2008) 0.87
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother (2014) 0.86
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother (1997) 0.85
Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1. Clin Exp Immunol (2000) 0.85
Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients. Br J Cancer (2001) 0.85
Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol (2013) 0.85
Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients. Environ Mol Mutagen (2008) 0.84
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother (2013) 0.84
High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro. Nanoscale Res Lett (2013) 0.84
Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology (2007) 0.84
A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture. Infect Immun (2000) 0.83
Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med (2010) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small (2014) 0.83
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther (2003) 0.82
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules. Protein Sci (2005) 0.81
Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res (2014) 0.80
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules (2014) 0.79
pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL. Br J Cancer (1996) 0.79
Tumor antigens discovery: perspectives for cancer therapy. Mol Med (1997) 0.79
Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol (2012) 0.79
Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients. Oncoimmunology (2013) 0.79
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol (2012) 0.78
Mart1 is located on mouse chromosome 19 and is excluded as a candidate for ep and ru. Mamm Genome (1997) 0.77
Going Pro to enhance T-cell immunogenicity: easy as π? Eur J Immunol (2013) 0.76
CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology (2014) 0.75
A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen. J Biol Chem (2016) 0.75
Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Sci Rep (2016) 0.75
Cancer immunotherapy: potential involvement of mediators. Mediators Inflamm (1997) 0.75
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res (2014) 0.75
Oligoclonality of CD8+ T cells in breast cancer patients. Mol Med (1997) 0.75
Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity. Immunology (2001) 0.75
T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones. J Immunol Methods (2016) 0.75
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science (1992) 8.68
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 7.78
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A (1987) 6.90
The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science (1989) 6.89
Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A (1981) 6.67
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science (1992) 5.99
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 5.76
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell (1995) 5.50
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett (1989) 4.75
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Rapid analysis of amino acid phenylthiohydantoins by high-performance liquid chromatography. Anal Biochem (1977) 4.64
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med (1989) 3.89
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
NMR structure of a specific DNA complex of Zn-containing DNA binding domain of GATA-1. Science (1993) 3.74
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1990) 3.53
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J (1999) 3.46
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J (2001) 3.37
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Isolation and characterization of linear deoxyribonucleic acid plasmids from Kluyveromyces lactis and the plasmid-associated killer character. J Bacteriol (1981) 3.30
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature (2001) 3.25
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J (1992) 3.21
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A (1997) 3.19
Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol (1992) 3.10
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05